High-grade gliomas (HGGs) are the most common cause of cancer-related death in children and diffuse midline gliomas (DMGs) are the most rapidly fatal HGGs with a median survival of less than 12 months. Despite numerous clinical trials involving aggressive therapies, there has been no meaningful improvement in patient survival in over two decades.
Neuroblastoma is the most common cancer in the first year of life, metastasizes in over 60% of patients, and once metastasis has occurred, 5-year survival rates decrease to less than 50%. Current therapy often relies on a large number of chemotherapeutic agents, and survival remains poor in comparison to other childhood malignancies.
Chris loves baseball – he has a history of playing for his high school team and is a longtime fan of the San Francisco Giants. However, when he was in high school, Chris began having strange symptoms. Today, Chris is a three-time survivor of glioblastoma.
